Please Wait
Applying Filters...
menu
    • menu
    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-08-25

    Virtual Booth

    An Enquiry

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-08-25

    Virtual Booth

    An Enquiry

    Menu

    Pegcetacoplan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apellis snatches broad kidney Disease Expansion for Empaveli
    Apellis snatches broad kidney Disease Expansion for Empaveli

    29 Jul 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/apellis-counters-novartis-broad-label-empaveli-kidney-disease

    FIERCE PHARMA
    29 Jul 2025
    Share Share
    Apellis' Five Abstracts Accepted for Oral Presentation at ASRS
    Apellis' Five Abstracts Accepted for Oral Presentation at ASRS

    15 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/15/3115449/0/en/Apellis-Announces-Five-Abstracts-Accepted-for-Oral-Presentation-at-the-American-Society-of-Retina-Specialists-ASRS-Annual-Scientific-Meeting.html

    GLOBENEWSWIRE
    15 Jul 2025
    Share Share
    Apellis to Get $300M from Royalty Deal with Sobi for Aspaveli
    Apellis to Get $300M from Royalty Deal with Sobi for Aspaveli

    01 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/01/3108202/0/en/Apellis-to-Receive-up-to-300-Million-from-Royalty-Purchase-Agreement-with-Sobi-for-Ex-U-S-Royalties-of-Aspaveli-systemic-pegcetacoplan.html

    GLOBENEWSWIRE
    01 Jul 2025
    Share Share
    Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN
    Apellis, Sobi Report Ph3 Data For EMPAVELI In C3G, IC-MPGN

    06 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/06/3095128/0/en/Apellis-and-Sobi-Announce-EMPAVELI-pegcetacoplan-Showed-Sustained-Efficacy-at-One-Year-in-Phase-3-Study-for-C3G-and-Primary-IC-MPGN.html

    GLOBENEWSWIRE
    06 Jun 2025
    Share Share
    Sobi's Aspaveli® 52-week Phase 3 Valiant Data in Nephrology
    Sobi's Aspaveli® 52-week Phase 3 Valiant Data in Nephrology

    03 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/invitation-sobis-aspaveli---52-week-phase-3-valiant-data-in-nephrology-302471733.html

    PR NEWSWIRE
    03 Jun 2025
    Share Share
    Apellis' Syfovre faces tough road ahead in GA market
    Apellis' Syfovre faces tough road ahead in GA market

    14 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/apellis-weak-syfovre-quarter-signals-uphill-climb-geographic-atrophy-med-mizuho

    FIERCE PHARMA
    14 May 2025
    Share Share